Adlarity Patent Expiration

Adlarity is a drug owned by Corium Inc. It is protected by 9 US drug patents filed from 2022 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 11, 2038. Details of Adlarity's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11679086 Systems comprising a composite backing and methods for long term transdermal administration
May, 2037

(12 years from now)

Active
US9993466 Donepezil transdermal delivery system
Jul, 2037

(13 years from now)

Active
US10016372 Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
Jul, 2037

(13 years from now)

Active
US10300025 Donepezil transdermal delivery system
Jul, 2037

(13 years from now)

Active
US10307379 Donepezil transdermal delivery system
Jul, 2037

(13 years from now)

Active
US11103463 Methods for treating alzheimer's disease with donepezil transdermal system
Jul, 2037

(13 years from now)

Active
US11648214 Systems and methods for long term transdermal administration
Sep, 2037

(13 years from now)

Active
US10835499 Systems and methods for long term transdermal administration
May, 2038

(13 years from now)

Active
US10966936 Systems comprising a composite backing and methods for long term transdermal administration
Aug, 2038

(14 years from now)

Active


FDA has granted several exclusivities to Adlarity. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Adlarity, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Adlarity.

Exclusivity Information

Adlarity holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2025. Details of Adlarity's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 11, 2025

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Adlarity is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Adlarity's family patents as well as insights into ongoing legal events on those patents.

Adlarity's family patents

Adlarity has patent protection in a total of 11 countries. It's US patent count contributes only to 38.2% of its total global patent coverage. Click below to unlock the full patent family tree for Adlarity.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Adlarity's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 11, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Adlarity Generics:

Donepezil Hydrochloride is the generic name for the brand Adlarity. 39 different companies have already filed for the generic of Adlarity, with Chartwell Rx having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Adlarity's generic





About Adlarity

Adlarity is a drug owned by Corium Inc. It is used for treating mild, moderate, and severe dementia of the Alzheimer's type. Adlarity uses Donepezil Hydrochloride as an active ingredient. Adlarity was launched by Corium in 2022.

Market Authorisation Date:

Adlarity was approved by FDA for market use on 11 March, 2022.

Active Ingredient:

Adlarity uses Donepezil Hydrochloride as the active ingredient. Check out other Drugs and Companies using Donepezil Hydrochloride ingredient

Treatment:

Adlarity is used for treating mild, moderate, and severe dementia of the Alzheimer's type.

Dosage:

Adlarity is available in system form for transdermal use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
5MG/DAY SYSTEM Prescription TRANSDERMAL
10MG/DAY SYSTEM Prescription TRANSDERMAL